Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02631174
Recruitment Status : Completed
First Posted : December 16, 2015
Last Update Posted : January 25, 2019
Sponsor:
Collaborator:
Grifols Biologicals, LLC
Information provided by (Responsible Party):
Children's Hospital Medical Center, Cincinnati

Brief Summary:

The potential role of ATIII in achieving and maintaining adequate anticoagulation in pediatric patients on the heart-lung machine has recently taken on increased importance as caregivers strive to mitigate the risk for clinically significant clotting problems. It is known that ATIII levels are decreased in normal neonates and infants less than 6 months of age relative to older children and adults and become even further decreased in critically ill neonates and infants, including those with congenital heart disease. The current utilization of ATIII in the context of support on a heart-lung machine is based on pharmacokinetic data derived from adult subjects with congenital ATIII deficiency. There is a gap in knowledge as to the appropriate frequency of ATIII repletion, best method of monitoring, and mode of administration in critically ill neonates and infants receiving support on a heart-lung machine.Our long-term goal is to determine if antithrombin (ATIII) can effectively change the coagulation system in patients undergoing heart-lung machine support. The objective of this proposal, which is our first step in pursuit of that goal, is to determine the pharmacokinetics of ATIII in neonates and infants. Our central hypothesis is that ATIII will have different pharmacokinetic properties in neonates and infants than adults and these properties will be affected by the use of heart-lung machine.

This research will result in critical data on the pharmacokinetics of ATIII in neonates and infants receiving heart-lung machine support. This contribution is significant because it is the first step in a continuum of research that is expected to lead to the development of a therapeutic strategy employing ATIII that will facilitate improved modulation of the coagulation cascade to prevent significant clotting and bleeding complications in pediatric patients requiring heart-lung machine support.


Condition or disease Intervention/treatment Phase
Extracorporeal Membrane Oxygenation Complication Cardiopulmonary Bypass Drug: Antithrombin III Phase 1

Detailed Description:

This is a single-site, prospective, open-label, pharmacokinetic study of hpATIII in neonates and infants. Patients admitted to the Cardiac Intensive Care Unit (CICU) and the Neonatal Intensive Care Unit (NICU) at Cincinnati Children's Hospital Medical Center (CCHMC) will be enrolled. Participants will be enrolled into one of three cohorts depending on whether they are scheduled for ECMO, CPB, or neither, and based on age (neonate or infant).

Two doses of hpATIII will be used; one according to current labelling for hpATIII and one that accounts for the additional circuit volume from ECMO or CPB. Pharmacokinetic measurements will be obtained for all groups at baseline prior to administration of hpATIII and at multiple defined times up to 120 hrs following each administration of hpATIII.

Administration of hpATIII is standard of care at CCHMC for participants undergoing ECMO. The standard dose administered for clinical care is (120 - baseline AT activity level) x weight (kg) / 1.4. For participants not undergoing ECMO for clinical care, or for those undergoing ECMO but receiving an adjusted dose for additional circuit volume , the administration of hpATIII is considered research.

The duration of the study at CCHMC is expected to be 2.5 years. This includes 24 months for recruitment and data collection, and 6 months for data analysis and report writing.

Individual participants will be in the study for approximately 120 hours (5 days) following administration of hpATIII. If participants receive more than 1 dose, they will be in the study for approximately 120 hours following each dose of hpATIII received.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 27 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support
Study Start Date : June 2015
Actual Primary Completion Date : June 2018
Actual Study Completion Date : June 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
No Intervention: cohort 1
Cohort 1 (Aim 1) - 6 participants Cohort 1 will be comprised of 6 neonates (≤28 days of age) admitted to the CICU or NICU who are neither undergoing ECMO nor CPB. Cohort 1 will receive a single dose of ATIII by short 15 minute infusion.
Active Comparator: cohort 2.1

• Cohort 2.1 - 6 neonates undergoing ECMO.

  • Three participants will receive a single dose 15 minute infusion of hpATIII that is dose adjusted to account for additional circuit volume followed by a single dose 15 minute infusion of ATIII that is not dose adjusted to account for circuit volume
  • Three participants will receive a single dose 15 minute infusion of hpATIII that is not dose adjusted to account for circuit volume followed by a single dose 15 minute infusion of hpATIII that is dose adjusted to account for additional circuit volume
Drug: Antithrombin III
We are comparing neonates and infants on ECMP or CPB receiving ATIII, the dose of which is calculated to account for circuit volume, and compared with those not accounting for circuit volume

Active Comparator: cohort 2.2

• Cohort 2.2 - 12 neonates who will undergo open-heart surgery with CPB

  • Six participants will receive a single dose 15 minute infusion of ATIII that is dose adjusted to account for additional circuit volume.
  • Six participants will receive a single dose 15 minute infusion of ATIII that is not dose adjusted to account for circuit volume
Drug: Antithrombin III
We are comparing neonates and infants on ECMP or CPB receiving ATIII, the dose of which is calculated to account for circuit volume, and compared with those not accounting for circuit volume

Active Comparator: cohort 2.3

• Cohort 2.3 - 12 infants who will undergo open-heart surgery with CPB

  • Six participants will receive a single dose 15 minute infusion of ATIII that is dose adjusted to account for additional circuit volume.
  • Six participants will receive a single dose 15 minute infusion of ATIII that is not dose adjusted to account for circuit volume
Drug: Antithrombin III
We are comparing neonates and infants on ECMP or CPB receiving ATIII, the dose of which is calculated to account for circuit volume, and compared with those not accounting for circuit volume

Active Comparator: cohort 3
Cohort 3 (Aim 3) - 6 participants Six participants (neonates or infants) who will undergo ECMO and receive ATIII as standard of care will be enrolled and have a baseline ATIII level measured within 6 hours of ATIII administration and repeated within 15 minutes of initiation of extracorporeal support. If post-support level is < 80% normal activity then an ATIII level will be repeated and participants will be assigned to one of two hpATIII dosing regimens in which one formula accounts for additional circuit volume and one formula does not account for additional circuit volume, as described in section 7.4. Upon completion and 120 hr follow up after the first dose, participants still having ATIII activity less than 80% will then receive a second dose
Drug: Antithrombin III
We are comparing neonates and infants on ECMP or CPB receiving ATIII, the dose of which is calculated to account for circuit volume, and compared with those not accounting for circuit volume




Primary Outcome Measures :
  1. Aim 1:To determine the pharmacokinetics of a single dose of hpATIII in neonates not undergoing ECMO or CPB. [ Time Frame: participants in cohort 1 will have sampling up to 36 hrs after receiving their single dose of ATIII ]
    Blood samples (0.5 mL) for analysis of plasma ATIII concentration will be drawn at specific time points, e.g. before and after the dose of ATIII is given ,together with coagulation labs such as prothrombin/ thrombin anti thrombin complex and CBC, PT/PTT/INR at baseline, 12 and 24 hrs only.If clinical labs exist, those will be used instead for that time point.

  2. Aim 2:To determine the pharmacokinetics of a single dose of hpATIII in neonates and infants undergoing ECMO or CPB [ Time Frame: participants will be followed for 120hrs after recieving their single dose of ATIII ]
    Blood samples (0.5 mL) for analysis of plasma ATIII concentration will be drawn at specific time points, e.g.before and after the dose of ATIII is given,together with coagulation labs such as prothrombin/ thrombin anti thrombin complex and CBC, PT/PTT/INR at baseline, 12 and 24 hrs only. If clinical labs exist, those will be used instead for that time point.

  3. Aim 3:To determine the pharmacokinetics of hpATIII administered by continuous infusion in neonates and infants undergoing ECMO [ Time Frame: participants will be followed for a period of 120hrs after recieving half the dose as a bolus and the rest as a continuous infusion ]
    Blood samples (0.5 mL) for analysis of plasma ATIII concentration will be drawn at specific time points, e.g.before and after the dose of ATIII is given,together with coagulation labs such as prothrombin/ thrombin anti thrombin complex and CBC, PT/PTT/INR at baseline, 12 and 24 hrs only. If clinical labs exist, those will be used instead for that timepoint.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 1 Year   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 1. Neonates less than or equal to 28 days of age OR Infants between 29 days and 1 year of age;
  • 2. ATIII activity less than 80% at time of screening;

Exclusion Criteria:

  • Subjects who meet any of the following criteria will be excluded from the study:

    1. Known or suspected bleeding disorder;
    2. Neonates with gestational age <36 weeks;
    3. Neonates with evidence of intracranial hemorrhage on routine cranial ultrasound;
    4. Documented infection (sepsis);
    5. Patients who require post-cardiotomy ECMO;
    6. Patients who require E-CPR; and/or
    7. Neonates or infants deemed to be at increased risk as judged by the investigator or for whom administration of hpATIII is not in their best interest
    8. Additional Exclusion for Cohort 1 only: Transfusion of whole blood, fresh frozen plasma (FFP), platelets or cryoprecipitate prior to study;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02631174


Locations
Layout table for location information
United States, Ohio
Cincinnati Childrens Hospital Medical Center
Cincinnati, Ohio, United States, 45229
Sponsors and Collaborators
Children's Hospital Medical Center, Cincinnati
Grifols Biologicals, LLC
Investigators
Layout table for investigator information
Principal Investigator: David Cooper, MD Cincinnati Childrens Hospital Medical Center